# Micafungin

## Mycamine inj 50mg

| 藥物代碼 | IMYC |
| :--- | :--- |
| 適應症 | Candidemia, acute disseminated candidiasis, and Candida peritonitis and abscesses, Esophageal candidiasis, Prophylaxis of Candida infection in hematopoietic stem cell transplantation |
| 副作用 | &gt;10%:Cardiovascular: Tachycardia \(3% to 26%\), localized phlebitis \(with peripheral administration; 5% to 19%\)Central nervous system: Headache \(2% to 44%\), insomnia \(4% to 37%\), anxiety \(?23%\), dizziness \(13%\)Dermatologic: Pruritus \(pediatric patients ages 3 days through 16 years: ?33%; adults 6%\), skin rash \(2% to 30%\), urticaria \(pediatric patients ages 3 days through 16 years: ?19%; adults &lt;5%\)Endocrine & metabolic: Hypokalemia \(14% to 18%\), hypomagnesemia \(6% to 13%\)Gastrointestinal: Diarrhea \(7% to 77%\), nausea \(7% to 71%\), vomiting \(7% to 66%\), abdominal pain \(2% to 35%\), abdominal distension \(pediatric patients ages 3 days through 16 years: 2% to 19%\), mucositis \(14%\), constipation \(11%\)Genitourinary: Decreased urine output \(pediatric patients ages 3 days through 16 years: ?23%\), hematuria \(pediatric patients ages 3 days through 16 years: ?23%\)Hematologic & oncologic: Neutropenia \(5% to 75%\), thrombocytopenia \(4% to 75%\), anemia \(pediatric patients ages 3 days through 16 years: 13% to 51%; adults 3% to 10%\), febrile neutropenia \(?16%\)Hepatic: Increased serum ALT \(pediatric patients ages 3 days through 16 years: ?16%; adults 5%\), abnormal hepatic function tests \(pediatric patients ages 3 days through 16 years: &lt;15%; adults 4%\), hyperbilirubinemia \(pediatric patients ages 3 days through 16 years: &lt;15%; adults &lt;1%\)Renal: Renal failure \(pediatric patients ages 3 days through 16 years: &lt;15%\)Miscellaneous: Fever \(pediatric patients ages 3 days through 16 years: 9% to 61%; adults 7% to 20%\), infusion related reaction \(pediatric patients ages 3 days through 16 years: ?16%; adults &lt;5%\) |
| 禁忌 | Hypersensitivity to micafungin, other echinocandins, or any component of the formulation |
| 藥物保存方式 | N/A |
| 用法用量 | Treatment of patients w/ candidemia, acute disseminated candidiasis, candida peritonitis & abscesses 100 mg/day. Treatment of esophageal candidiasis 150 mg/day. Prophylaxis of Candida infections in hematopoeitic stem cell transplantation \(HSCT\) recipients 50 mg/day. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | IVD: 5mL N/S, D5W\(需減少泡沫形成\) |
| 輸注點滴液 | 【N/S】 可選  【D5W】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | 給藥濃度0.5~1.5mg/mL,建議滴注1小時以上 |
| 注意事項 | N/A |

